During Monday's "Lightning Round" segment of Mad Money, one caller asked Jim Cramer about the prospects for CRISPR Therapeutics (CRSP) : "A company like this isn't bought on earnings, it's bought on speculation. As long as you're OK with that, I'll bless it," responded Cramer.
More from Investing
The key issue in a better market is to put more money to work and have more exposure.
Outside of the ETF launch which could generate flow into the crypto space, it is important to ask what the real theme is for Bitcoin.
Let's see if this is the time to step on the accelerator.